Anakinra for rheumatoid arthritis

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Mertens, Marty ^a   Singh, Jasvinder A ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

Adult; Antirheumatic agents *therapeutic use ; Arthritis, rheumatoid *drug therapy ; Humans; Interleukin 1 receptor antagonist protein *therapeutic use ; Randomized controlled trials as topic

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOLIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CELLULITIS; CINAHL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COCHRANE LIBRARY; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG CARCINOGENICITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL STATUS; HUMAN; IMAGE ANALYSIS; IMMUNOTHERAPY; INFECTION; INJECTION SITE REACTION; JOINT RADIOGRAPHY; LOW DRUG DOSE; MEDLINE; META ANALYSIS; MONOTHERAPY; MORTALITY; OPPORTUNISTIC INFECTION; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TUBERCULOSIS; VISUAL ANALOG SCALE;

EID: 68349092914     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005121.pub3     Document Type: Review

References (73)

1. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al.Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis & Rheumatism 1998;41(12):2196-2204 (Pubitemid 29009378)
2. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al.Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 2002;46(3):614-624 (Pubitemid 34214243)
3. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al.A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Annals of the Rheumatic Diseases 2004;63(9):1062-1068 (Pubitemid 39120355)
4. Fleischmann RM, Schechtman J, Bennet R, Handel ML, Burmeister GR, Tesser J, et al.Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis & Rheumatism 2003;48(4):927-934 (Pubitemid 36418234)
5. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al.Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis & Rheumatism 2004;50(5):1412-1419 (Pubitemid 38608062)
6. Amgen, Inc. Anakinra FDA briefing information. www.fda.gov/ohrms/dockets/ ac/01/briefing/3779bI.htm 8/21/2001.
7. Bresnihan B. The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. Seminars in Arthritis & Rheumatism 2001;30(5 Suppl 2):17-20. (Pubitemid 32467131)
8. Bresnihan B. Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis. Annals of the Rheumatic Diseases 2002;61(Suppl 2):ii74-7. (Pubitemid 35221721)
9. Bresnihan B. Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives. Clinical & Experimental Rheumatology 2002;20(5 Suppl 27):S32-4. (Pubitemid 35174751)
10. Bresnihan B, Newmark R, Robbins S, Genant HK, Bresnihan B, Newmark R, et al.Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. Arthritis & Rheumatism 2004;31(6):1103-1111
11. Burls A, Jobanputra P. The trials of anakinra. Lancet 2004;364:827-828
12. Calabrese LH. Anakinra treatment of patient with rheumatoid arthritis. Annals of Pharmacotherapy 2002;36:1204-1209 (Pubitemid 34755799)
13. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin- 1 receptor antagonist in patients with rheumatoid arthritis. Arthritis & Rheumatism 1996;39(7):1092-1101 (Pubitemid 26240220)
14. Choy EHS, Smith C, Dore CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005;44(11):1414-1421 (Pubitemid 41631866)
15. Cohen, S. B, J. M. Woolley, Chan W, Anakinra 960180 Study G. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. Journal of Rheumatology 2003;30(2):225-231 (Pubitemid 36152581)
16. Cohen SB, Strand V, Aguilar D, Ofman JJ. Patient- versus physician- reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology 2004;43(6):704-711 (Pubitemid 38811416)
17. De La Mata Llord J, Crespo RG, Manzano JM. Treatment of rheumatoid arthritis with anakinra: A systematic review. Reumatologia Clinica 2007;3(4):153-158 (Pubitemid 47434485)
18. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis & Rheumatism 2005;52(7):1960-1967
19. Dougados M, Combe B, Beveridge T, Bourdeix I, Lallemand A, Amor B, et al.IX 207-887 in rheumatoid arthritis. Arthritis & Rheumatism 1992;35(9):999-1006.
20. Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, et al.Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis & Rheumatism 1996;39(2):257-265 (Pubitemid 26069676)
21. Fleishmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents. Clinical & Experimental Rheumatology 2002;20(5 Suppl 27):S35-41.
22. Fleischmann RM, Tesser J, et al.Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006;65(8):1006-1012 (Pubitemid 44133261)
23. Garces K. Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis. Issues in Emerging Health Technologies 2001;16:1-4.
24. Garrood T, Scott DL. Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Biodrugs 2001;15(8):543-561 (Pubitemid 32939232)
25. Genant, H. K. Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. Seminars in Arthritis & Rheumatism 2001;30(5, suppl 2):26-32.
26. Haraoui B, Keystone EC. Anakinra, a new pharmacotherapeutic approach to treating rheumatoid arthritis. Today's Therapeutic Trends 2003;21(1):49-59. (Pubitemid 36278039)
27. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis & Rheumatism 2000;43(5):1001-1009 (Pubitemid 30368176)
28. Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology 2003;42(1):6-13. (Pubitemid 36131560)
29. Loft AG, Tarp U, Thomsen BS, Loft AGR, Tarp U, Thomsen BS. [Anakinra in the treatment of rheumatoid arthritis]. Ugeskrift for Laeger 2003;165(39):3720-3724
30. National Horizon Scanning Centre. Anakinra for rheumatoid arthritis - horizon scanning review. Birmingham: National Horizon Scanning Centre 2001; Vol.4.
31. Nixon R, Bansback N, Brennan A. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology 2007;46(7):1140-1147 (Pubitemid 47050618)
32. Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical I, Nuki G, et al.Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 2002;46(11):2838-2846 (Pubitemid 35315874)
33. Paget SA. Efficacy of anakinra in bone: comparison to other biologics. Advances in Therapy 2002;19(1):27-39.
34. Rau R, Sander O, Musikic P. [Treatment of chronic polyarthritis with a human recombinant interleukin 1 receptor antagonist]. Zeitschrift fur Rheumatologie 1998;57(5):312-319
35. Rau R, Sander O, Wassenberg S. Erosion healing in rheumatoid arthritis after anakinra treatment. Annals of the Rheumatic Diseases 2003;62(7):671-673 (Pubitemid 36760568)
36. Riente, L. The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis. [Italian]. Reumatismo 2004;56(1, suppl 1):74-79 (Pubitemid 38596239)
37. Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al.The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis & Rheumatism 2004;50(6):1752-1760 (Pubitemid 38725086)
38. Schwetz BA. From the Food and Drug Administration. JAMA 2002;287(1):33.
39. Strand V, Landewe R, Van der Heijde D. Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis. Annals of the Rheumatic Diseases 2002;61(Suppl 2):ii64-66. (Pubitemid 35221718)
40. Strand V. Longer term benefits of treating rheumatoid arthritis: Assessment of radiographic damage and physical function in clinical trials. Clinical and Experimental Rheumatology 2004;22(5 Suppl 35):S57-64. (Pubitemid 39328356)
41. Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. Journal of Rheumatology 2004;31(4):649-654 (Pubitemid 38451249)
42. Tomoo T, Sumida T, et al."[Anakinra for therapy of rheumatoid arthritis]. Nippon Rinsho - Japanese Journal of Clinical Medicine 2005;63(Suppl 1):534-7.
43. Watt I, Cobby M. Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. Seminars in Arthritis & Rheumatism 2001;30(5 suppl 2):21-25 (Pubitemid 32467132)
44. Zundorf I, Dingermann T, Zundorf I, Dingermann T. [Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis]. Pharmazie in Unserer Zeit 2003;32(5):376-383
45. Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 2002;41:972-980 (Pubitemid 35049925)
46. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis & Rheumatism2002;46(2):328-346
47. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism 1988;31:315-324
48. Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al.Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003785]
49. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al.Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004525]
50. FDA website. Product approval information: Anakinra. www.fda.gov, 2003.
51. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al.American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis & Rheumatism 1995;38(6):727-735
52. Felson, American College of Rheumatology Committee to Reevaluate Improvement Criteria. A Proposed Revision to the ACR20: The Hybrid Measure of American College of Rheumatology Response. Arthritis & Rheumatism 2007;57(2):193-202.
53. Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clinical and Experimental Rheumatology 2005;23(S39):S93-9. (Pubitemid 46657516)
54. Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis & Rheumatism 1980;23:137-145
55. Gravallese EM. Bone destruction in arthritis. Annals of Rheumatic Disease 2002;61(Suppl ii):ii84-86. [DOI: 10.1136/ard.61.suppl-2.ii84]
56. Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Statistics in Medicine 2004;23:1663-1682
57. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis & Rheumatism 2000;43:1478-1487 (Pubitemid 30452465)
58. Krishnan E, Sokka T, Häkkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire Disability Index: benchmarking disability in the general population. Arthritis & Rheumatism 2004;50:953-960 (Pubitemid 38326196)
59. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologic Diagnosis (Stockholm) 1977;18(4):481-491 (Pubitemid 8198049)
60. Lipsky RE. Rheumatoid arthritis. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL editor(s). Harrison's Principles of Internal Medicine. 16. McGraw-Hill, 2005.
61. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2]
62. O'Dell JR. Rheumatoid arthritis. Current Rheumatology Diagnosis and Treatment. Imboden J, Hellman DB, Stone JH.. Vol. 1, McGraw-Hill, 2004.
63. Pincus T, Summey JA, Soraci SA, Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis & Rheumatism 1983;26:1346-1353 (Pubitemid 14231480)
64. Prevoo MLL, Van't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LBA, Van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis & Rheumatism 1995;38:44-48
65. Prevoo MLL, Van Gestel AM, Van't Hof MA, Van Rijswijk MH, Van de Putte LBA, Van Riel PLCM. Remission in a prospective study of patients with rheumatoid arthritis. British Journal of Rheumatology 1996;35:1101-1105
66. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141-155 (Pubitemid 29093257)
67. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis & Rheumatism 1971;14(6):706-720
68. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al.Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigator Group. Arthritis & Rheumatism 2000;43:506-514 (Pubitemid 30394940)
69. Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V, et al.Evidence-based Rheumatology. BMJ Books, 2004.
70. van der Heijde DMFM, van Riel PL, Nuver-Zwart IH, Gribnau FW, Van de Puttte LB. Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-1038 (Pubitemid 19123055)
71. van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. Journal of Rheumatology 1993;20(3):579-581
72. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis & Rheumatism 1996;39(1):34-40.
73. Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. Journal of Rheumatology 1993;20:557. (Pubitemid 23102493)